Innovate CORP 8-K filings

Innovate Corp. announced an agreement to sell its DBM Global subsidiary for $650 million in cash and stock, a move intended to significantly reduce the company's outstanding debt.

Innovate Corp. announced a significant increase in second quarter 2026 revenue and a swing to net income, driven by robust performance in its Infrastructure segment and strategic financial maneuvers.

Innovate Corp. has entered into supplemental indentures to modify interest payment terms on its senior secured notes, allowing for payment-in-kind interest and extending a promissory note maturity.

Innovate Corp. announced that its subsidiary, DBM Global Inc., will pay a cash dividend of approximately $12 million, with Innovate Corp. expecting to receive about $11 million.

Innovate Corp. shareholders approved all management proposals at the 2026 Annual Meeting, including director elections and equity plan amendments.

Innovate Corp. announced the successful closing of a refinancing transaction for its broadcasting subsidiary and an agreement to sell a controlling interest in that subsidiary to CONX Corp.

INNOVATE Corp. reported a 33% increase in first-quarter revenue to $364.8 million, driven by its Infrastructure segment, while also achieving key regulatory milestones in Life Sciences.

INNOVATE Corp. announced that its subsidiary, DBM Global Inc., will pay a $3 million cash dividend, with INNOVATE receiving approximately $2.7 million.

INNOVATE Corp.'s equity investment, MediBeacon, announced its transdermal GFR monitor and reusable sensor received EU CE Mark certification, enabling potential European clinical trials.

INNOVATE Corp. announced robust fourth-quarter and full-year 2025 results, driven by significant infrastructure growth and strategic advancements in life sciences and spectrum.

INNOVATE Corp.'s equity interest MediBeacon announced its Transdermal GFR article was recognized as a 2025 Editors Choice by JASN, coinciding with its commercialization launch.

INNOVATE Corp.'s operating subsidiary, DBM Global Inc., announced a $5 million cash dividend, with INNOVATE expecting to receive $4.6 million.

INNOVATE Corp.'s affiliate, MediBeacon, received FDA approval for its next-generation TGFR™ System, a point-of-care kidney function assessment tool.

INNOVATE Corp. reports strong Q3 2025 revenue growth driven by Infrastructure, alongside key regulatory approvals and debt refinancing efforts, despite overall nine-month losses and mandatory asset sales.

INNOVATE Corp.'s equity investment, MediBeacon, received regulatory approval from China's NMPA to sell its Transdermal GFR System, including Lumitrace injection, for kidney function assessment.

INNOVATE Corp.'s operating subsidiary, DBM Global Inc., announced it will pay an $8.8 million cash dividend, with INNOVATE expecting to receive approximately $8 million.

INNOVATE Corp.'s portfolio company, R2 Technologies, announced an 88% revenue increase in Q2 2025 for its Glacial Skin technology, driven by global expansion.

INNOVATE Corp. reported a 22.7% decline in Q2 2025 revenue to $242.0 million and a net loss of $22.0 million, despite successful debt refinancing and growth in its Life Sciences segment.

INNOVATE Corp. successfully closed a series of debt refinancing transactions, extending maturities for over 80% of its outstanding debt, including new senior secured and convertible notes, while adjusting terms and covenants.

INNOVATE Corp. announced strong early participation in its exchange offer for senior secured notes, exceeding the minimum threshold and extending the early exchange premium to all participants.

INNOVATE Corp. announced that its operating subsidiary, DBM Global Inc., will pay a $4.4 million cash dividend, with INNOVATE expecting to receive approximately $4 million as the largest stockholder.

INNOVATE Corp. announced a series of indebtedness refinancing transactions aimed at extending the maturities of its various debt instruments, including convertible and senior secured notes, revolving credit, and other promissory notes.

INNOVATE Corp. announced the successful election of its four director nominees, advisory approval of executive compensation, and a decision for annual Say-on-Pay votes at its June 12, 2025 Annual Meeting of Stockholders.

INNOVATE Corp. announced that its operating subsidiary, DBM Global Inc., will pay a cash dividend of approximately $5.5 million, with INNOVATE expecting to receive $5 million as the largest stockholder.

DBM Global Inc., a subsidiary of INNOVATE Corp., has entered into an amended and restated credit agreement providing $220 million in senior secured debt financing.

INNOVATE Corp. reports Q1 2025 results, highlighting FDA approval for MediBeacon's TGFR system and a significant increase in DBM Global's backlog, while consolidated revenue and Adjusted EBITDA decline year-over-year.

INNOVATE Corp. reported a decrease in consolidated revenue for Q4 2024, driven by its Infrastructure segment, though offset by growth in Life Sciences and Spectrum.

INNOVATE Corp. has amended its credit agreement to extend the maturity date of its senior secured revolving credit facility to August 1, 2025.

INNOVATE Corp. announces that its MediBeacon Transdermal GFR Monitor and TGFR Sensor have been approved by China's National Medical Products Administration (NMPA) for assessing kidney function.

INNOVATE Corp. announces FDA approval for its MediBeacon Transdermal GFR system, a novel point-of-care device for assessing kidney function without blood draws or urine analysis.